Betrixaban – the next direct factor Xa inhibitor?

References

• Chan NC, Bhagirath V, Eikelboom JW. Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag. 2015;11:343–51.
   PubMed Web of Science ®Google Scholar
• Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med. 2010;38(4 Suppl):S495–S501.
   PubMed Web of Science ®Google Scholar
• Heit JA. Epidemiology of venous thromboembolism. Nature reviews Cardiology. 2015;12(8):464–74.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98(4):756–64.
   PubMed Web of Science ®Google Scholar
• Vaughan P, Gardner J, Peters F, Wilmott R. Risk factors for venous thromboembolism in general surgical patients. Isr Med Assoc J. 2002;4(11):1037–9.
   PubMed Web of Science ®Google Scholar
• O’Reilly RF, Burgess IA, Zicat B. The prevalence of venous thromboembolism after hip and knee replacement surgery. Med J Aust. 2005;182(4):154–9.
   PubMed Web of Science ®Google Scholar
• Merli GJ. MAnagement of deep vein thrombosis in spinal cord injury. Chest. 1992;102(6_Supplement):652S–7S.
   Google Scholar
• Toker S, Hak DJ, Morgan SJ. Deep vein thrombosis prophylaxis in trauma patients. Thrombosis. 2011;2011:505373.
   PubMedGoogle Scholar
• Linnemann B, Weingarz L, Schindewolf M, et al. Prevalence of established risk factors for venous thromboembolism according to age. J Vasc Surg Venous Lymphat Disord. 2014;2(2):131–9.
   PubMedGoogle Scholar
• Anderson FA, Jr., Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I9–16.
   PubMed Web of Science ®Google Scholar
• Patel K, Chang JS, Chun LJ. Deep Venous Thrombosis Treatment & Management 2016 [cited.2016.Oct 07]. Available from: http://emedicine.medscape.com/article/1911303-treatment.
   Google Scholar
• Ita K. Transdermal delivery of heparin: physical enhancement techniques. Int J Pharm. 2015;496(2):240–9.
   PubMed Web of Science ®Google Scholar
• Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141 (2 Suppl):e152S–84S.
   PubMed Web of Science ®Google Scholar
• Blann AD. Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory. Br J Biomed Sci. 2014;71(4):158–67.
   PubMed Web of Science ®Google Scholar
• Saliba W. Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation. Am J Cardiovasc Drugs. 2015;15(5):323–35.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764–72.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808.
   PubMed Web of Science ®Google Scholar
• Shields AM, Lip GY. Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. J Intern Med. 2015;278(1):1–18.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Harrington R, Goldhaber SZ, et al. The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. Am Heart J. 2014;167(3):335–41.
   PubMed Web of Science ®Google Scholar
• Turpie AG, Bauer KA, Davidson BL, et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost. 2009;101(1):68–76.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom J, Dorian P, et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J. 2013;34(20):1498–505.
   PubMed Web of Science ®Google Scholar
• Hutchaleelaha A, Ye C, Song Y, Lorenz T, Gretler DD, Lanbing JL. Metabolism and Disposition of Betrixaban and Its Lack of Interaction with Major CYP Enzymes. 54th ASH Annual Meeting and Exposition 2012: Abstract 2266.
   Google Scholar
• Zhang P, Huang W, Wang L, et al. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenz amide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett. 2009;19(8):2179–85.
   PubMed Web of Science ®Google Scholar
• Chan NC, Hirsh J, Ginsberg JS, Eikelboom JW. Betrixaban (PRT054021): pharmacology, dose selection and clinical studies. Future Cardiol. 2014;10(1):43–52.
   PubMedGoogle Scholar
• Gomez-Outes A, Suarez-Gea ML, Lecumberri R, Terleira-Fernandez AI, Vargas-Castrillon E, Rocha E. Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. Vasc Health Risk Manag. 2013;9:207–28.
   PubMedGoogle Scholar
• Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. New England Journal of Medicine. 2016;375(6):534–44.
   PubMed Web of Science ®Google Scholar
• Morganroth J, Gretler DD, Hollenbach SJ, Lambing JL, Sinha U. Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study. Expert Opin Pharmacother. 2013;14(1):5–13.
   PubMed Web of Science ®Google Scholar
• ICH harmonised tripartite guideline. The clinical evaluation of qt/qtc interval prolongation and proarrhythmic potential for non antiarrhythmic drugs e14. 2005 [cited.2016.Oct 07]. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf.
   Google Scholar
• Pollack CV, Jr., Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015;373(6):511–20.
   PubMed Web of Science ®Google Scholar
• Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015.
   PubMed Web of Science ®Google Scholar
• A Study in Patients With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (NCT02329327) [cited.2016.Oct 07]. Available from: https://clinicaltrials.gov/ct2/show/NCT02329327?term=Andexanet+alfa&rank=3.
   Google Scholar
• Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban. New England Journal of Medicine. 2014;371(22):2141–2.
   PubMed Web of Science ®Google Scholar
• Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban (NCT02207257) [cited.2016.Oct 07]. Available from: https://clinicaltrials.gov/ct2/show/NCT02207257?term=PER977&rank=3.
   Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011;105(4):721–9.
   PubMed Web of Science ®Google Scholar
• Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–97.
   PubMed Web of Science ®Google Scholar
• Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012;40(12):2250–5.
   PubMed Web of Science ®Google Scholar
• Mani H, Lindhoff-Last E. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Design, Development and Therapy. 2014;8:789–98.
   PubMed Web of Science ®Google Scholar
• Stacy ZA, Call WB, Hartmann AP, Peters GL, Richter SK. Edoxaban: a comprehensive review of the pharmacology and clinical data for the management of atrial fibrillation and venous thromboembolism. Cardiol Ther. 2016.
   PubMedGoogle Scholar